Background: Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin’s lymphoma (HL) remain controversial. Patients and Methods: We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto’s method. Results: Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62–0.98 and P = 0.03). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00–1.89 and P = 0.05). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR (P = 0.28) although more breast cancers occurred with EF-RT (P = 0.04 and OR = 3.25). Conclusions: Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies. Key words: chemotherapy, Hodgkin’s lymphoma, meta-analysis, radiotherapy, second malignancies

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials / FRANKLIN J; PLUETSCHOW A; PAUS M; SPECHT L; ANSELMO AP; AVILES A; G. BITI; BOGATYREVA T; BONADONNA G; BRILLANT C; CAVALIERI E; DIEHL V; EGHBALI H; FERME C; HENRY-AMAR M; HOPPE R; HOWARD S; MEYER R; NIEDZWIECKI D; PAVLOVSKY S; RADFORD J; RAEMAEKERS J; RYDER D; SCHILLER P; SHAKHTARINA S; VALAGUSSA P; WILIMAS J; YAHALOM J. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 17:(2006), pp. 1749-1760.

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

BITI, GIAMPAOLO;
2006

Abstract

Background: Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin’s lymphoma (HL) remain controversial. Patients and Methods: We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto’s method. Results: Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62–0.98 and P = 0.03). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00–1.89 and P = 0.05). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR (P = 0.28) although more breast cancers occurred with EF-RT (P = 0.04 and OR = 3.25). Conclusions: Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies. Key words: chemotherapy, Hodgkin’s lymphoma, meta-analysis, radiotherapy, second malignancies
2006
17
1749
1760
FRANKLIN J; PLUETSCHOW A; PAUS M; SPECHT L; ANSELMO AP; AVILES A; G. BITI; BOGATYREVA T; BONADONNA G; BRILLANT C; CAVALIERI E; DIEHL V; EGHBALI H; FERME C; HENRY-AMAR M; HOPPE R; HOWARD S; MEYER R; NIEDZWIECKI D; PAVLOVSKY S; RADFORD J; RAEMAEKERS J; RYDER D; SCHILLER P; SHAKHTARINA S; VALAGUSSA P; WILIMAS J; YAHALOM J
File in questo prodotto:
File Dimensione Formato  
second malignancy HDG.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 812.29 kB
Formato Adobe PDF
812.29 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/250800
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact